A review: Fentanyl and non-pharmaceutical fentanyls

Drug and Alcohol Dependence

Volumn 171, Issue , 2017, Pages 107-116

  Suzuki, Joji ^a,b   El Haddad, Saria ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Fentanyl; Non pharmaceutical fentanyl; Opioid use disorder; Overdose

Indexed keywords

ALFENTANIL; ALPRAZOLAM; BUPRENORPHINE; CARFENTANIL; DIAMORPHINE; FENTANYL; FENTANYL DERIVATIVE; HYDROCODONE; LOFENTANIL; NALOXONE; NALTREXONE; NON PHARMACEUTICAL FENTANYL; OPIATE; OXYCODONE; PARACETAMOL; REMIFENTANIL; SUFENTANIL; UNCLASSIFIED DRUG; NARCOTIC ANALGESIC AGENT;

CITATION ANALYSIS; CLINICAL PHARMACOLOGY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MISUSE; DRUG OVERDOSE; DRUG TOLERABILITY; HUMAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; UNITED STATES; OPIOID-RELATED DISORDERS;

ANALGESICS, OPIOID; DRUG OVERDOSE; FENTANYL; HEROIN; HUMANS; OPIOID-RELATED DISORDERS; UNITED STATES;

EID: 85008354529     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2016.11.033     Document Type: Review

References (166)

1. Abel-Ollo, K., Talu, A., Vorobjov, S., Vals, K., Teder, P., Ahven, A., Denissov, G., 2011. 2011 National Report to the European Monitoring Centre for Drug and Drug Addiction, by the Reitox National Focal Point: Estonia : New developments, trends and in-depth information on selected issues.
2. Algren, D.A., Monteilh, C.P., Punja, M., Schier, J.G., Belson, M., Hepler, B.R., Schmidt, C.J., Miller, C.E., Patel, M., Paulozzi, L.J., Straetemans, M., Rubin, C., Fentanyl-associated fatalities among illicit drug users in Wayne County, Michigan (July 2005–May 2006). J. Med. Toxicol. 9 (2013), 106–115, 10.1007/s13181-012-0285-4.
3. Arens, A., Vo, K., Van Wijk, X., Lemos, N., Olson, K., Smollin, C., Adulterated Xanax: A Case Series From San Francisco. Poster Presented at the American College of Medical Toxicology (ACMT) Annual Scientific Meeting, 2016 URL http://www.acmt.net/_Library/2016_ASM_Posters/Abstract_14.pdf (Accessed July 28, 2016).
4. Belz, D., Lieb, J., Rea, T., Eisenberg, M.S., Naloxone use in a tiered-response emergency medical services system. Prehosp. Emerg. Care 10 (2006), 468–471, 10.1080/10903120600885134.
5. Biedrzycki, O.J., Bevan, D., Lucas, S., Fatal overdose due to prescription fentanyl patches in a patient with sickle cell/beta-thalassemia and acute chest syndrome: a case report and review of the literature. Am. J. Forensic Med. Pathol. 30 (2009), 188–190, 10.1097/PAF.0b013e318187de71.
6. Binswanger, I.A., Blatchford, P.J., Mueller, S.R., Stern, M.F., Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann. Intern. Med. 159 (2013), 592–600, 10.7326/0003-4819-159-9-201311050-00005.
7. Boyer, E.W., Management of opioid analgesic overdose. N. Engl. J. Med. 367 (2012), 146–155, 10.1056/NEJMra1202561.
8. Brittain, J.L., China white: the bogus drug. J. Toxicol. Clin. Toxicol. 19 (1982), 1123–1126.
9. Brodrick, J.E., Brodrick, C.K., Adinoff, B., Legal regimes surrounding naloxone access: considerations for prescribers. Am. J. Drug Alcohol Abuse 42 (2016), 117–128, 10.3109/00952990.2015.1109648.
10. Bryson, E.O., Silverstein, J.H., Addiction and substance abuse in anesthesiology. Anesthesiology 109 (2008), 905–917, 10.1097/ALN.0b013e3181895bc1.
11. Buajordet, I., Naess, A.-C., Jacobsen, D., Brørs, O., Adverse events after naloxone treatment of episodes of suspected acute opioid overdose. Eur. J. Emerg. Med. 11 (2004), 19–23.
12. Burns, G., DeRienz, R.T., Baker, D.D., Casavant, M., Spiller, H.A., Could chest wall rigidity be a factor in rapid death from illicit fentanyl abuse?. Clin. Toxicol. Phila, 2016, 10.3109/15563650.2016.1157722.
13. Centers for Disease Control and Prevention (CDC), Nonpharmaceutical fentanyl-related deaths–multiple states, april 2005-March 2007. MMWR Morb. Mortal. Wkly. Rep. 57 (2008), 793–796.
14. Centers for Disease Control and Prevention, 2015. Increases in Fentanyl Drug Confiscations and Fentanyl-related Overdose Fatalities.
15. Chandler, J., Newly Popular and Deadly Fentanyl Pills are Being Made in Orange County's Backyard. 2016, Orange Cty. Regist.
16. Chaturvedi, A.K., Rao, N.G., Baird, J.R., A death due to self-administered fentanyl. J. Anal. Toxicol. 14 (1990), 385–387.
17. Coppola, M., Mondola, R., AH-7921: a new synthetic opioid of abuse. Drug Alcohol Rev. 34 (2015), 109–110, 10.1111/dar.12216.
18. Coruh, B., Tonelli, M.R., Park, D.R., Fentanyl-induced chest wall rigidity. Chest 143 (2013), 1145–1146, 10.1378/chest.12-2131.
19. Cunningham, S.M., Haikal, N.A., Kraner, J.C., Fatal intoxication with acetyl fentanyl. J. Forensic Sci., 2015, 10.1111/1556-4029.12953.
20. D'Onofrio, G., O'Connor, P.G., Pantalon, M.V., Chawarski, M.C., Busch, S.H., Owens, P.H., Bernstein, S.L., Fiellin, D.A., Emergency department-Initiated Buprenorphine/Naloxone treatment for opioid dependence: a randomized clinical trial. JAMA 313 (2015), 1636–1644, 10.1001/jama.2015.3474.
21. Drug Enforcement Administration, 2006 Heroin Domestic Monitor Program [WWW Document]., 2007 URL http://lib.adai.uw.edu/pubs/DEAheroinreport2006.pdf (Accessed 6.1.16).
22. Drug Enforcement Administration, Rules – 2010 – Final Rule: Control of Immediate Precursor Used in the Illicit Manufacture of Fentanyl as a Schedule II Controlled Substance [WWW Document]. 2010 URL http://www.deadiversion.usdoj.gov/fed_regs/rules/2010/fr0629.htm (Accessed 3.30.16).
23. Drug Enforcement Administration, 2011 Heroin Domestic Monitor Program [WWW Document]. 2013 (URL http://info.publicintelligence.net/DEA-HeroinDMP-2011.pdf).
24. Drug Enforcement Administration, 2015a. National Heroin Threat Assessment Summary: DEA-DCT-DIR-039-15 [WWW Document]. URL https://www.dea.gov/divisions/hq/2015/hq052215_National_Heroin_Threat_Assessment_Summary.pdf (accessed 6.20.16).
25. Drug Enforcement Administration, 2015b. Special Report: Opiates and related drugs reported in NFLIS, 2009-2014 [WWW Document]. URL http://www.deadiversion.usdoj.gov/nflis/spec_rpt_opioids_2014.pdf (accessed 2.1.16).
26. Drug Enforcement Administration, 2015c. 2013 Heroin Domestic Monitor Program: DEA-DCW-DIR-059-15 [WWW Document]. URL https://ndews.umd.edu/sites/ndews.umd.edu/files/pubs/2013%20Heroin%20Domestic%20Monitor%20Program.pdf (accessed 6.16.15).
27. Drug Enforcement Administration, 2016a. Rules - 2016 - Notice of Intent: Temporary Placement of Butyryl Fentanyl and Beta-Hydroxythiofentanyl Into Schedule I [WWW Document]. URL http://www.deadiversion.usdoj.gov/fed_regs/rules/2016/fr0323_16.htm (accessed 4.22.16).
28. Drug Enforcement Administration, 2016b. Counterfeit Prescription Pills Containing Fentanyls: A Global Threat: DEA-DCT-DIB-021-16 [WWW Document]. URL https://www.dea.gov/docs/Counterfeit%20Prescription%20Pills.pdf (accessed 7.30.16).
29. Dahan, A., Aarts, L., Smith, T.W., Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology 112 (2010), 226–238, 10.1097/ALN.0b013e3181c38c25.
30. Darke, S., Duflou, J., The toxicology of heroin-related death: estimating survival times. Addict. Abingdon Engl., 2016, 10.1111/add.13429.
31. Darke, S., Hall, W., Heroin overdose: research and evidence-based intervention. J. Urban Health Bull. N. Y. Acad. Med. 80 (2003), 189–200, 10.1093/jurban/jtg022.
32. Darke, S., Williamson, A., Ross, J., Mills, K.L., Havard, A., Teesson, M., Patterns of nonfatal heroin overdose over a 3-year period: findings from the Australian treatment outcome study. J. Urban Health Bull. N. Y. Acad. Med. 84 (2007), 283–291, 10.1007/s11524-006-9156-0.
33. Davis, C.S., Carr, D., Legal changes to increase access to naloxone for opioid overdose reversal in the United States. Drug Alcohol Depend. 157 (2015), 112–120, 10.1016/j.drugalcdep.2015.10.013.
34. De Vos, V., Immobilisation of free-ranging wild animals using a new drug. Vet. Rec. 103 (1978), 64–68.
35. Denton, J.S., Donoghue, E.R., McReynolds, J., Kalelkar, M.B., An epidemic of illicit fentanyl deaths in cook county, illinois: september 2005 through april 2007. J. Forensic Sci. 53 (2008), 452–454, 10.1111/j.1556-4029.2008.00669.x.
36. Digiusto, E., Shakeshaft, A., Ritter, A., O'Brien, S., Mattick, R.P., NEPOD Research Group, Serious adverse events in the australian national evaluation of pharmacotherapies for opioid dependence (NEPOD). Addict. Abingdon Engl. 99 (2004), 450–460, 10.1111/j.1360-0443.2004.00654.x.
37. Dilokthornsakul, P., Moore, G., Campbell, J.D., Lodge, R., Traugott, C., Zerzan, J., Allen, R., Page, R.L., Risk factors of prescription opioid overdose among colorado medicaid beneficiaries. J. Pain 17 (2016), 436–443, 10.1016/j.jpain.2015.12.006.
38. Drug Enforcement Administration, Control of immediate precursor used in the illicit manufacture of fentanyl as a schedule II controlled substance. Final rule. Fed. Regist. 75 (2010), 37295–37299.
39. Drug Enforcement Administration (DEA), U.S. Department of Justice, Control of a chemical precursor used in the illicit manufacture of fentanyl as a List I chemical. Interim rule with request for comments. Fed. Regist. 72 (2007), 20039–20047.
40. Drug Enforcement Administration, Department of Justice, Schedules of controlled substances: temporary placement of acetyl fentanyl into schedule I. Final order. Fed. Regist. 80 (2015), 42381–42385.
41. Dunn, K.M., Saunders, K.W., Rutter, C.M., Banta-Green, C.J., Merrill, J.O., Sullivan, M.D., Weisner, C.M., Silverberg, M.J., Campbell, C.I., Psaty, B.M., Von Korff, M., Opioid prescriptions for chronic pain and overdose: a cohort study. Ann. Intern. Med. 152 (2010), 85–92, 10.7326/0003-4819-152-2-201001190-00006.
42. Edinboro, L.E., Poklis, A., Trautman, D., Lowry, S., Backer, R., Harvey, C.M., Fatal fentanyl intoxication following excessive transdermal application. J. Forensic Sci. 42 (1997), 741–743.
43. Ellement, J.R., Boston Police Warn Fake Oxycodone Pills Are Made of Fentanyl [WWW Document]. Boston Globe. 2016 URL https://www.bostonglobe.com/metro/2016/06/23/boston-police-warning-fake-oxycodone-pills-are-made-fentanyl-and-could-fatal/8FwlTQkNeVHJlg4XeIttgK/story.html (Accessed 7.28.16).
44. Evans, J.M., Hogg, M.I., Lunn, J.N., Rosen, M., Degree and duration of reversal by naloxone of effects of morphine in conscious subjects. Br. Med. J. 2 (1974), 589–591.
45. Fareed, A., Buchanan-Cummings, A.M., Crampton, K., Grant, A., Drexler, K., Reversal of overdose on fentanyl being illicitly sold as heroin with naloxone nasal spray: a case report. Am. J. Addict. Am. Acad. Psychiatr. Alcohol. Addict. 24 (2015), 388–390, 10.1111/ajad.12230.
46. Fernando, D., Fentanyl-laced heroin. JAMA, 265, 1991, 10.1001/jama.1991.03460220050029 2962–2962.
47. Food and Drug Administration, FDA Issues Public Health Advisory on the Fentanyl Patch [WWW Document]. 2005 URL http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108461.htm (Accessed 3.24.16).
48. Food and Drug Administration, FDA Issues Second Safety Warning on Fentanyl Skin Patch: Deaths and Serious Injuries from Improper Use [WWW Document]. 2007 URL http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109046.htm (Accessed 3.1.16).
49. Foster, D., Upton, R., Christrup, L., Popper, L., Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann. Pharmacother. 42 (2008), 1380–1387, 10.1345/aph.1L168.
50. Franko, K., A New Threat in Fight Against Overdoses: Elephant Sedative [WWW Document]. USA News. 2016 URL http://www.usnews.com/news/news/articles/2016-07-28/a-new-threat-in-fight-against-overdoses-elephant-sedative (Accessed 10.19.16).
51. Fried, A., Anthony, R., Cseko, A., Gaither, C., Schulman, E., 2008. The Price and Purity of Illicit Drugs: 1981–2007: IDA Paper P-4369.
52. Friesen, K.J., Woelk, C., Bugden, S., Safety of fentanyl initiation according to past opioid exposure among patients newly prescribed fentanyl patches. CMAJ 188 (2016), 648–653, 10.1503/cmaj.150961.
53. Garriott, J.C., Rodriguez, R., Di Maio, V.J., A death from fentanyl overdose. J. Anal. Toxicol. 8 (1984), 288–289.
54. Gibson, G., Fentanyl Is Deadly Mix: Laced Heroin Blamed for Boost in Fatal Overdoses in U.S. Baltim. 2006, Sun.
55. Gladden, R.M., Martinez, P., Seth, P., Fentanyl law enforcement submissions and increases in synthetic opioid-Involved overdose deaths – 27 states, 2013–2014. MMWR Morb. Mortal. Wkly. Rep. 65 (2016), 837–843, 10.15585/mmwr.mm6533a2.
56. Glass, P.S., Iselin-Chaves, I.A., Goodman, D., Delong, E., Hermann, D.J., Determination of the potency of remifentanil compared with alfentanil using ventilatory depression as the measure of opioid effect. Anesthesiology 90 (1999), 1556–1563.
57. Goldberger, B.A., Cone, E.J., Grant, T.M., Caplan, Y.H., Levine, B.S., Smialek, J.E., Disposition of heroin and its metabolites in heroin-related deaths. J. Anal. Toxicol. 18 (1994), 22–28.
58. Gomes, T., Mamdani, M.M., Dhalla, I.A., Paterson, J.M., Juurlink, D.N., Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch. Intern. Med. 171 (2011), 686–691, 10.1001/archinternmed.2011.117.
59. Gonzales, R., Molina, S., 4 Arrested After Suspected Synthetic Heroin Lab Found in Baldwin Park. 2016, San Gabriel Val. Trib.
60. Hadland, S.E., DeBeck, K., Kerr, T., Nguyen, P., Simo, A., Montaner, J.S., Wood, E., Use of a medically supervised injection facility among street youth. J. Adolesc. Health 55 (2014), 684–689, 10.1016/j.jadohealth.2014.04.013.
61. Halliburton, J.R., The pharmacokinetics of fentanyl, sufentanil and alfentanil: a comparative review. AANA J. 56 (1988), 229–233.
62. Harm Reduction Coalition, 2001. H is for Heroin.
63. Harm Reduction Coalition, Getting off Right: A Safety Manual for Injection Drug Users [WWW Document]. 2012 URL http://harmreduction.org/wp-content/uploads/2011/12/getting-off-right.pdf (Accessed 5.1.16).
64. Harper, M.H., Hickey, R.F., Cromwell, T.H., Linwood, S., The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man. J. Pharmacol. Exp. Ther. 199 (1976), 464–468.
65. Hempstead, K., Yildirim, E.O., Supply-side response to declining heroin purity: fentanyl overdose episode in new jersey. Health Econ., 2013, 10.1002/hec.2937.
66. Henderson, G.L., Designer drugs: past history and future prospects. J. Forensic Sci. 33 (1988), 569–575.
67. Henderson, G.L., Fentanyl-related deaths: demographics, circumstances, and toxicology of 112 cases. J. Forensic Sci. 36 (1991), 422–433.
68. Hibbs, J., Perper, J., Winek, C.L., An outbreak of designer drug–related deaths in Pennsylvania. JAMA 265 (1991), 1011–1013.
69. Hug, C.C., Murphy, M.R., Fentanyl disposition in cerebrospinal fluid and plasma and its relationship to ventilatory depression in the dog. Anesthesiology 50 (1979), 342–349.
70. Hull, M.J., Juhascik, M., Mazur, F., Flomenbaum, M.A., Behonick, G.S., Fatalities associated with fentanyl and co-administered cocaine or opiates. J. Forensic Sci., 2007, 1383–1388, 10.1111/j.1556-4029.2007.00564.x.
71. Janssen Pharmaceutica Products, 2003. Duragesic: Fentanyl transdermal system. Full prescribing information.
72. Jin, W.Q., Xu, H., Zhu, Y.C., Fang, S.N., Xia, X.L., Huang, Z.M., Ge, B.L., Chi, Z.Q., Studies on synthesis and relationship between analgesic activity and receptor affinity for 3-methyl fentanyl derivatives. Sci. Sin. 24 (1981), 710–720.
73. Jungerman, F.S., Palhares-Alves, H.N., Carmona, M.J.C., Conti, N.B., Malbergier, A., Anesthetic drug abuse by anesthesiologists. Rev. Bras. Anestesiol. 62 (2012), 375–386, 10.1016/S0034-7094(12)70138-1.
74. Kappel, N., Toth, E., Tegner, J., Lauridsen, S., A qualitative study of how Danish drug consumption rooms influence health and well-being among people who use drugs. Harm. Reduct. J., 13, 2016, 20, 10.1186/s12954-016-0109-y.
75. Katselou, M., Papoutsis, I., Nikolaou, P., Spiliopoulou, C., Athanaselis, S., AH-7921: the list of new psychoactive opioids is expanded. Forensic Toxicol. 33 (2015), 195–201, 10.1007/s11419-015-0271-z.
76. Kerr, D., Kelly, A.-M., Dietze, P., Jolley, D., Barger, B., Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addict. Abingdon Engl. 104 (2009), 2067–2074, 10.1111/j.1360-0443.2009.02724.x.
77. Kintz, P., Villain, M., Dumestre, V., Cirimele, V., Evidence of addiction by anesthesiologists as documented by hair analysis. Forensic Sci. Int. 153 (2005), 81–84, 10.1016/j.forsciint.2005.04.033.
78. Kitch, B.B., Portela, R.C., Effective use of naloxone by law enforcement in response to multiple opioid overdoses. Prehosp. Emerg. Care 20 (2016), 226–229, 10.3109/10903127.2015.1076097.
79. Klausner, J.M., Caspi, J., Lelcuk, S., Khazam, A., Marin, G., Hechtman, H.B., Rozin, R.R., Delayed muscular rigidity and respiratory depression following fentanyl anesthesia. Arch. Surg. Chic. Ill 1960:123 (1988), 66–67.
80. Koehntop, D.E., Rodman, J.H., Fentanyl pharmacokinetics in patients undergoing renal transplantation. Pharmacotherapy 17 (1997), 746–752.
81. Kram, T.C., Cooper, D.A., Allen, A.C., Behind the identification of China white. Anal. Chem. 53 (1981), 1379A–1386A.
82. Kramer, C., Tawney, M., A fatal overdose of transdermally administered fentanyl. J. Am. Osteopath. Assoc. 98 (1998), 385–386.
83. Kumar, K., Morgan, D.J., Crankshaw, D.P., Determination of fentanyl and alfentanil in plasma by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. 419 (1987), 464–468.
84. LaBarbera, M., Wolfe, T., Characteristics, attitudes and implications of fentanyl use based on reports from self-identified fentanyl users. J. Psychoactive Drugs 15 (1983), 293–301, 10.1080/02791072.1983.10471966.
85. Labroo, R.B., Paine, M.F., Thummel, K.E., Kharasch, E.D., Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab. Dispos. Biol. Fate Chem. 25 (1997), 1072–1080.
86. Larochelle, M.R., Liebschutz, J.M., Zhang, F., Ross-Degnan, D., Wharam, J.F., Opioid prescribing after nonfatal overdose and association with repeated overdose: a cohort study. Ann. Intern. Med. 164 (2016), 1–9, 10.7326/M15-0038.
87. Levine, B., Goodin, J.C., Caplan, Y.H., A fentanyl fatality involving midazolam. Forensic Sci. Int. 45 (1990), 247–251.
88. Lichtor, J.L., Sevarino, F.B., Joshi, G.P., Busch, M.A., Nordbrock, E., Ginsberg, B., The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. Anesth. Analg. 89 (1999), 732–738.
89. Liebschutz, J.M., Crooks, D., Herman, D., et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern. Med., 2014, 10.1001/jamainternmed.2014.2556.
90. Lilleng, P.K., Mehlum, L.I., Bachs, L., Morild, I., Deaths after intravenous misuse of transdermal fentanyl. J. Forensic Sci. 49 (2004), 1364–1366.
91. Lim, J.K., Bratberg, J.P., Davis, C.S., Green, T.C., Walley, A.Y., Prescribe to prevent: overdose prevention and naloxone rescue kits for prescribers and pharmacists. J. Addict. Med., 2016, 10.1097/ADM.0000000000000223.
92. Lozier, M.J., Boyd, M., Stanley, C., Ogilvie, L., King, E., Martin, C., Lewis, L., Acetyl fentanyl, a novel fentanyl analog, causes 14 overdose deaths in rhode island, march–May 2013. J. Med. Toxicol. 11 (2015), 208–217, 10.1007/s13181-015-0477-9.
93. Marquardt, K.A., Tharratt, R.S., Inhalation abuse of fentanyl patch. J. Toxicol. Clin. Toxicol. 32 (1994), 75–78.
94. Mars, S.G., Fessel, J.N., Bourgois, P., Montero, F., Karandinos, G., Ciccarone, D., Heroin-related overdose: the unexplored influences of markets, marketing and source-types in the United States. Soc. Sci. Med. 1982:140 (2015), 44–53, 10.1016/j.socscimed.2015.06.032.
95. Marshall, B.D.L., Milloy, M.-J., Wood, E., Montaner, J.S.G., Kerr, T., Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet Lond. Engl. 377 (2011), 1429–1437, 10.1016/S0140-6736(10)62353-7.
96. Martin, M., Hecker, J., Clark, R., Frye, J., Jehle, D., Lucid, E.J., Harchelroad, F., China White epidemic: an eastern United States emergency department experience. Ann. Emerg. Med. 20 (1991), 158–164.
97. Martin, T.L., Woodall, K.L., McLellan, B.A., Fentanyl-related deaths in Ontario, Canada: toxicological findings and circumstances of death in 112 cases (2002–2004). J. Anal. Toxicol. 30 (2006), 603–610.
98. Massachusetts Department of Public Health, 2016. Data Brief: Opioid-related Overdose Deaths Among Massachusetts Residents.
99. Matejczyk, R.J., Fentanyl related overdose. J. Anal. Toxicol. 12 (1988), 236–238.
100. McAuley, A., Lindsay, G., Woods, M., Responsible management and use of a personal take-home naloxone supply: a pilot project. Drugs Educ. Prev. Policy 17 (2010), 388–399.
101. McCann, E., Temenos, C., Mobilizing Drug Consumption Rooms: inter-place networks and harm reduction drug policy. Health Place 31 (2015), 216–223, 10.1016/j.healthplace.2014.12.009.
102. McClain, D.A., Hug, C.C., Intravenous fentanyl kinetics. Clin. Pharmacol. Ther. 28 (1980), 106–114.
103. McIntyre, I.M., Trochta, A., Gary, R.D., Wright, J., Mena, O., An acute butyr-fentanyl fatality: a case report with postmortem concentrations. J. Anal. Toxicol., 2015, 10.1093/jat/bkv138.
104. McIntyre, I.M., Gary, R.D., Joseph, S., Stabley, R., A fatality related to the synthetic opioid U-47700: postmortem concentration distribution. J. Anal. Toxicol., 2016, 10.1093/jat/bkw124.
105. Mohr, A.L.A., Friscia, M., Papsun, D., Kacinko, S.L., Buzby, D., Logan, B.K., Analysis of novel synthetic opioids U-47700, U-50488 and furanyl fentanyl by LC–MS/MS in postmortem casework. J. Anal. Toxicol., 2016, 10.1093/jat/bkw086.
106. Murray, R.A., Doering, P.L., Boothby, L.A., Merves, M.L., McCusker, R.R., Chronister, C.W., Goldberger, B.A., Putting an Ecstasy test kit to the test: harm reduction or harm induction?. Pharmacotherapy 23 (2003), 1238–1244.
107. National Institute on Drug Abuse, 2012. Fentanyl.
108. National Center for Biotechnology Information, 2016a. Carfentanil: National Center for Biotechnology Information. PubChem Compound Database; CID=62156 [WWW Document]. URL https://pubchem.ncbi.nlm.nih.gov/compound/62156 (accessed 7.1.16).
109. National Center for Biotechnology Information, 2016b. Lofentanil: National Center for Biotechnology Information. PubChem Compound Database; CID=10070040 [WWW Document]. URL https://pubchem.ncbi.nlm.nih.gov/compound/10070040 (accessed 7.1.16).
110. Neale, J., Strang, J., Naloxone–does over-antagonism matter? Evidence of iatrogenic harm after emergency treatment of heroin/opioid overdose. Addict. Abingdon Engl. 110 (2015), 1644–1652, 10.1111/add.13027.
111. Nelson, L., Schwaner, R., Transdermal fentanyl: pharmacology and toxicology. J. Med. Toxicol. 5 (2009), 230–241.
112. Osterwalder, J.J., Naloxone–for intoxications with intravenous heroin and heroin mixtures–harmless or hazardous? A prospective clinical study. J. Toxicol. Clin. Toxicol. 34 (1996), 409–416.
113. Panagiotou, I., Mystakidou, K., Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications. Expert Rev. Anticancer Ther. 10 (2010), 1009–1021, 10.1586/era.10.77.
114. Pare, E.M., Monforte, J.R., Gault, R., Mirchandani, H., A death involving fentanyl. J. Anal. Toxicol. 11 (1987), 272–275.
115. Peterson, A.B., Gladden, R.M., Delcher, C., Spies, E., Garcia-Williams, A., Wang, Y., Halpin, J., Zibbell, J., McCarty, C.L., DeFiore-Hyrmer, J., DiOrio, M., Goldberger, B.A., Increases in fentanyl-Related overdose deaths – florida and ohio, 2013–2015. MMWR Morb. Mortal. Wkly. Rep. 65 (2016), 844–849, 10.15585/mmwr.mm6533a3.
116. Pfeiffer, S., 2016. Overwhelmed by overdoses, clinic offers a room for highs.
117. Poklis, A., Backer, R., Urine concentrations of fentanyl and norfentanyl during application of Duragesic transdermal patches. J. Anal. Toxicol. 28 (2004), 422–425.
118. Poklis, J., Poklis, A., Wolf, C., Mainland, M., Hair, L., Devers, K., Chrostowski, L., Arbefeville, E., Merves, M., Pearson, J., Postmortem tissue distribution of acetyl fentanyl, fentanyl and their respective nor-metabolites analyzed by ultrahigh performance liquid chromatography with tandem mass spectrometry. Forensic Sci. Int. 257 (2015), 435–441, 10.1016/j.forsciint.2015.10.021.
119. Poklis, J., Poklis, A., Wolf, C., Hathaway, C., Arbefeville, E., Chrostowski, L., Devers, K., Hair, L., Mainland, M., Merves, M., Pearson, J., Two fatal intoxications involving butyryl fentanyl. J. Anal. Toxicol., 2016, 10.1093/jat/bkw048.
120. Poklis, A., Fentanyl: a review for clinical and analytical toxicologists. J. Toxicol. Clin. Toxicol. 33 (1995), 439–447.
121. Potier, C., Laprévote, V., Dubois-Arber, F., Cottencin, O., Rolland, B., Supervised injection services: what has been demonstrated? A systematic literature review. Drug Alcohol Depend. 145 (2014), 48–68, 10.1016/j.drugalcdep.2014.10.012.
122. Reeves, M.D., Ginifer, C.J., Fatal intravenous misuse of transdermal fentanyl. Med. J. Aust. 177 (2002), 552–553.
123. Reynolds, L., Rauck, R., Webster, L., DuPen, S., Heinze, E., Portenoy, R., Katz, N., Charapata, S., Wallace, M., Fisher, D.M., Relative analgesic potency of fentanyl and sufentanil during intermediate-term infusions in patients after long-term opioid treatment for chronic pain. Pain 110 (2004), 182–188, 10.1016/j.pain.2004.03.024.
124. Robertson, T.M., Hendey, G.W., Stroh, G., Shalit, M., Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose. Prehosp. Emerg. Care 13 (2009), 512–515, 10.1080/10903120903144866.
125. Rogers, J.S., Rehrer, S.J., Hoot, N.R., Acetylfentanyl: an emerging drug of abuse. J. Emerg. Med., 2015, 10.1016/j.jemermed.2015.10.014.
126. Rosenberg, M., Drug abuse in oral and maxillofacial training programs. J. Oral Maxillofac. Surg. 44 (1986), 458–462.
127. Rosenblum, A., Cruciani, R.A., Strain, E.C., Cleland, C.M., Joseph, H., Magura, S., Marsch, L.A., McNicholas, L.F., Savage, S.R., Sundaram, A., Portenoy, R.K., Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol. J. Opioid Manag. 8 (2012), 369–382, 10.5055/jom.2012.0137.
128. Rudd, R.A., Aleshire, N., Zibbell, J.E., Gladden, R.M., Increases in drug and opioid overdose deaths – United States, 2000–2014. MMWR Morb. Mortal. Wkly. Rep. 64 (2016), 1378–1382, 10.15585/mmwr.mm6450a3.
129. Salazar, R., Dubow, J., Delayed posthypoxic leukoencephalopathy following a morphine overdose. J. Clin. Neurosci. 19 (2012), 1060–1062, 10.1016/j.jocn.2012.01.001.
130. Schellinger, K., Officer Safety: Heroin/fentanyl.Erie Crime Analysis Center, New York. [WWW Document]. 2014 http://www.cnyems.org/documents/listings/heroin%20fentanyl%20officer%20safety%206-11-15.pdf (Accessed April, 21, 2016).
131. Scholz, J., Steinfath, M., Schulz, M., Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update. Clin. Pharmacokinet. 31 (1996), 275–292, 10.2165/00003088-199631040-00004.
132. Schumann, H., Erickson, T., Thompson, T.M., Zautcke, J.L., Denton, J.S., Fentanyl epidemic in Chicago, illinois and surrounding cook county. Clin. Toxicol. Phila Pa 46 (2008), 501–506, 10.1080/15563650701877374.
133. Semaan, S., Fleming, P., Worrell, C., Stolp, H., Baack, B., Miller, M., Potential role of safer injection facilities in reducing HIV and hepatitis C infections and overdose mortality in the United States. Drug Alcohol Depend. 118 (2011), 100–110, 10.1016/j.drugalcdep.2011.03.006.
134. Silsby, H.D., Kruzich, D.J., Hawkins, M.R., Fentanyl citrate abuse among health care professionals. Mil. Med. 149 (1984), 227–228.
135. Silverstein, J.H., Rieders, M.F., McMullin, M., Schulman, S., Zahl, K., An analysis of the duration of fentanyl and its metabolites in urine and saliva. Anesth. Analg. 76 (1993), 618–621.
136. Smialek, J.E., Levine, B., Chin, L., Wu, S.C., Jenkins, A.J., A fentanyl epidemic in maryland 1992. J. Forensic Sci. 39 (1994), 159–164.
137. Spies E., Peterson A., Garcia-Williams A., Halpin J., Gladden M., Zibbell J., McCarty C., 2016. Undetermined risk factors for fentanyl-related overdose deaths—Ohio, 2015 (EpiAid 2016-003) Trip Report −Epi2.
138. Sporer, K.A., Acute heroin overdose. Ann. Intern. Med. 130 (1999), 584–590.
139. Stanley, T.H., The history and development of the fentanyl series. J. Pain Symptom Manage. 7 (1992), S3–7.
140. Stanley, T.H., The fentanyl story. J. Pain 15 (2014), 1215–1226, 10.1016/j.jpain.2014.08.010.
141. Stoeckel, H., Schüttler, J., Magnussen, H., Hengstmann, J.H., Plasma fentanyl concentrations and the occurrence of respiratory depression in volunteers. Br. J. Anaesth. 54 (1982), 1087–1095.
142. Strang, J., McCambridge, J., Best, D., Beswick, T., Bearn, J., Rees, S., Gossop, M., Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ 326 (2003), 959–960, 10.1136/bmj.326.7396.959.
143. Streisand, J.B., Varvel, J.R., Stanski, D.R., Le Maire, L., Ashburn, M.A., Hague, B.I., Tarver, S.D., Stanley, T.H., Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 75 (1991), 223–229.
144. Streisand, J.B., Bailey, P.L., LeMaire, L., Ashburn, M.A., Tarver, S.D., Varvel, J., Stanley, T.H., Fentanyl-induced rigidity and unconsciousness in human volunteers. Incidence duration, and plasma concentrations. Anesthesiology 78 (1993), 629–634.
145. Substance Abuse and Mental Health Services Administration, 2014. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-48, HHS Publication No. (SMA) 14–4863.
146. Substance Abuse and Mental Health Services Administration, 2014. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-48, HHS Publication No. (SMA) 14–4863.
147. Sutter, M.E., Gerona, R., Davis, M.T., Roche, B.M., Colby, D.K., Chenoweth, J.A., Adams, A.J., Owen, K.P., Ford, J.B., Black, H., Albertson, T.E., Fatal fentanyl: one pill can kill. Acad. Emerg. Med., 2016, 10.1111/acem.13034.
148. Suzuki, J., DeVido, J., Kalra, I., Mittal, L., Shah, S., Zinser, J., Weiss, R.D., Initiating buprenorphine treatment for hospitalized patients with opioid dependence: a case series. Am. J. Addict. Am. Acad. Psychiatr. Alcohol. Addict. 24 (2015), 10–14, 10.1111/ajad.12161.
149. Tateishi, T., Krivoruk, Y., Ueng, Y.F., Wood, A.J., Guengerich, F.P., Wood, M., Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth. Analg. 82 (1996), 167–172.
150. Tharp, A.M., Winecker, R.E., Winston, D.C., Fatal intravenous fentanyl abuse: four cases involving extraction of fentanyl from transdermal patches. Am. J. Forensic Med. Pathol. 25 (2004), 178–181.
151. Thompson, J.G., Baker, A.M., Bracey, A.H., Seningen, J., Kloss, J.S., Strobl, A.Q., Apple, F.S., Fentanyl concentrations in 23 postmortem cases from the hennepin county medical examiner's office. J. Forensic Sci. 52 (2007), 978–981, 10.1111/j.1556-4029.2007.00481.x.
152. Turock, M.K., Watts, D.J., Mude, H., Prestosh, J., Stoltzfus, J., Fentanyl-laced heroin: a report from an unexpected place. Am. J. Emerg. Med. 27 (2009), 237–239, 10.1016/j.ajem.2008.09.043.
153. Vaughn, R.L., Bennett, C.R., Fentanyl chest wall rigidity syndrome–a case report. Anesth. Prog. 28 (1981), 50–51.
154. Vo, K.T., van Wijk, X.M.R., Lynch, K.L., Wu, A.H.B., Smollin, C.G., Counterfeit Norco Poisoning Outbreak – San Francisco Bay Area, California, March 25-April 5, 2016. MMWR Morb. Mortal. Wkly. Rep. 65 (2016), 420–423, 10.15585/mmwr.mm6516e1.
155. Volkow, N.D., McLellan, A.T., Opioid abuse in chronic Pain–Misconceptions and mitigation strategies. N. Engl. J. Med. 374 (2016), 1253–1263, 10.1056/NEJMra1507771.
156. Volkow, N.D., Frieden, T.R., Hyde, P.S., Cha, S.S., Medication-assisted therapies–tackling the opioid-overdose epidemic. N. Engl. J. Med. 370 (2014), 2063–2066, 10.1056/NEJMp1402780.
157. WKRC, Law Enforcement, Drug Users Warned About Carfentanil [WWW Document]. 2016 URL http://local12.com/news/local/law-enforcement-drug-users-warned-about-carfentanil (Accessed 7.28.16).
158. Walley, A.Y., Xuan, Z., Hackman, H.H., Quinn, E., Doe-Simkins, M., Sorensen-Alawad, A., Ruiz, S., Ozonoff, A., Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ, 346, 2013, f174.
159. Walley, A., Optimizing Safety in Patients with Addictions [WWW Document]. 2015, Boston Med. Cent. URL http://www.bumc.bu.edu/care/files/2015/06/03.-WALLEY-2015-CRIT-Optimizing-Safety.pdf (Accessed 4.21.16).
160. Ward, C.F., Ward, G.C., Saidman, L.J., Drug abuse in anesthesia training programs. A survey: 1970 through 1980. JAMA 250 (1983), 922–925.
161. Warner-Smith, M., Darke, S., Lynskey, M., Hall, W., Heroin overdose: causes and consequences. Addict. Abingdon Engl. 96 (2001), 1113–1125, 10.1080/09652140120060716.
162. Wermeling, D.P., Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access. Ther. Adv. Drug Saf. 6 (2015), 20–31, 10.1177/2042098614564776.
163. Williams, H., Norman, M., Safer injecting: individual harm reduction advice. CPsychol, R.P.Bs., DClinPsy, AFBPsS, FRCPsych, A.M.M., ChB, MSc, Arnold, K., (eds.) Injecting Illicit Drugs., 2005, Blackwell Publishing Ltd., 135–148.
164. Williams, A.V., Marsden, J., Strang, J., Training family members to manage heroin overdose and administer naloxone: randomized trial of effects on knowledge and attitudes. Addict. Abingdon Engl. 109 (2014), 250–259, 10.1111/add.12360.
165. Woodall, K.L., Martin, T.L., McLellan, B.A., Oral abuse of fentanyl patches (Duragesic): seven case reports. J. Forensic Sci. 53 (2008), 222–225, 10.1111/j.1556-4029.2007.00597.x.
166. Wyman, J.R., Warning Against Misusing of Fentanyl Analgesic Skin Patch. [WWW Document]. 1994, Food Drug Adm. URL http://www3. scienceblog.com/community/older/archives/M/1/fda0986.htm (Accessed 6.15.16).